Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate

American Journal of Hematology

Volumn 81, Issue 8, 2006, Pages 582-589

  Firozvi, Kashif ^a   Deveras, Ruby Anne E ^a   Kessler, Craig M ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Hypercoagulability; Low molecular weight heparin; Recombinant activated factor VIIa (RFVIIa)

Indexed keywords

BLOOD CLOTTING FACTOR 7; ENOXAPARIN; HEMOGLOBIN; LOW MOLECULAR WEIGHT HEPARIN; VITAMIN K GROUP;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; BOLUS INJECTION; CASE REPORT; FEMALE; HUMAN; HYPERCOAGULABILITY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; PROTHROMBIN TIME; SINGLE DRUG DOSE; VENOUS THROMBOEMBOLISM;

ADULT; DRUG TOXICITY; FACTOR VII; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; RECOMBINANT PROTEINS; RISK FACTORS; THROMBOPHILIA; TREATMENT OUTCOME;

EID: 33745970762     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20652     Document Type: Article

References (31)

1. Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP, Briet E. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340:152-156.
2. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160:181-188.
3. Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. J Am Med Assoc 2004;292:89-96.
4. Montalescot G, Polle V, Collet JP, Leprince P, Bellanger A, Gandjbakhch I, Thomas D. Low-molecular-weight heparin after mechanical heart valve replacement. Circulation 2000;101:1083-1086.
5. Batchelor WB, Mahaffey KW, Berger PB, Deutsch E, Meier S, et al. A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial. J Am Coll Cardiol 2001;38:1608-1613.
6. Antman EM, Kereiakes DJ. Antithrombotic therapy in unstable angina/non-ST elevation myocardial infarction: the evolving role of low-molecular-weight heparin. J Invas Cardiol 2000;12:E1-E4, discussion E25-E28.
7. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355:1936-1942.
8. Alexander KP, Chen AY, Roe MT, Newby K, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. J Am Med Assoc 2005;294:3108-3116.
9. Holst J, Lindblad B, Bergqvist D, Garre K, Nielsen H, Hedner U, Ostergaard PB. Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteers Blood Coagul Fibrinolys 1994;5:795-803.
10. Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol 1991;28:3-5.
11. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002;137:884-888.
12. Hu Q, Brady JO. Recombinant activated factor VII for treatment of enoxaparin-induced bleeding. Mayo Clin Proc 2004;79:827.
13. Ng HJ, Koh LP, Lee LH. Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low-molecular-weight heparin and aspirin. Ann Hematol 2003;82:257-258.
14. Bijsterveld NR, Vink R, van Aken BE, Fennema H, Peters RJ, Meijers JC, Buller HR, Levi M. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004;124:653-658.
15. Lisman T, Bijisteveld NR, Adelmeijer J, Meijers JC, Levi M, Nieuwenhuis HK, DeGroot PG. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost 2003;1:2368-2373.
16. Chan S, Kong M, Minning DM, Hedner U, Marder VJ. Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low-molecular-weight heparin. J Thromb Haemost 2003;1:760-765.
17. Hedner U. General haemostatic agents - fact or fiction? Pathophysiol Haemost Thromb 2002;32:Suppl 1:33-36.
18. Bijsterveld NR, Moons AH, Boekholdt SM, van Aken BE, Fennema H, Peters RJ, Meijers JC, Buller HR, Levi M. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002;106:2550-2554.
19. Johannessen M, Nielsen G, Nordfang O. Comparison of the factor VII: C clot analysis and a modified activated factor VII analysis for monitoring factor VII activity in patients treated with recombinant activated factor VII (NovoSeven). Blood Coagul Fibrinolys 2000;11:S159-S164.
20. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005;33:883-890.
21. Aledort LM. Comparative thrombotic events incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004;10:1700-1708.
22. Hoffman M, Monroe DM, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolys 1998;9:p.S61-S65.
23. Kessler CM. New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate. Curr Opin Hematol 2000;7:408-413.
24. Gallistl S, Cvim G, Muntean W. Recombinant factor VIIa does not induce hypercoagulability in vitro. Thromb Haemost 1999; 81:245-249.
25. Bara L, Planes A, Samana MM. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low-molecular-weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol 1999;104:230-240.
26. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T. Recombinant activated factor VII intracerebral hemorrhage trial investigators, recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352:777-785.
27. Erhardtsen E, Nony P, Dechavanne M, Ffrench P, Boissel JP, Hedner U. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolys 1998;9: 741-748.
28. Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolys 2003;14:469-477.
29. Huvers F, Slappendel R, Benraad B, van Hellemondt G, van Kraaij M. Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid. Neth J Med 2005;63: 184-186.
30. Gerotziafas GT, Depasse F, Chakroun T, Samama MM, Elalamy I. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thromb Haemost 2004;91:531-537.
31. Natarajan MK, Velianou JL, Turpie AG, Mehta SR, Raco D, Goodhart DM, Afzal R, Ginsberg JS. A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions. Am Heart J 2006;151:175.